<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187924</url>
  </required_header>
  <id_info>
    <org_study_id>SIMEOX-003</org_study_id>
    <nct_id>NCT04187924</nct_id>
  </id_info>
  <brief_title>Effects of SIMEOX on Airway Clearance in Cystic Fibrosis</brief_title>
  <official_title>Effects of the Addition of the SIMEOX Device on Autogenic Drainage in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the contribution of SIMEOX technology on the effectiveness of
      bronchial drainage.

      This is a crossover study to evaluate the contribution of SIMEOX on the effectiveness of
      bronchial drainage (verified by the amount of sputum secretions, the rheology of sputum
      secretions and the subjective sensation of ease of sputum) in patients with cystic fibrosis.

      Patients will perform, in randomized order (1) a 30-min session of autogenic drainage, (2) a
      30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during
      and after the session. The two sessions will be performed with minimum washout time of 24
      hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of sputum secretion</measure>
    <time_frame>30-min</time_frame>
    <description>Total wet weight and dry weight of sputum collected in the 24-h following each intervention will be quantified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mucus viscoelasticity</measure>
    <time_frame>30-min</time_frame>
    <description>Change in rheological properties of the sputum before and after each intervention will be analyzed using a rheometer. We will use the Rheomuco (Rheonova) reometer to obtain the differences in elasticity (G'), viscosity (G')' and elastic modulus ratio (tanδ) of the secretions collected before and after each intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective feeling of ease to expectorate</measure>
    <time_frame>3-min</time_frame>
    <description>A Visual Analogue Scale (VAS) will be used to measure subjective feeling of ease of expectoration during each intervention.
The visual analogue scale (VAS) is a semi-objective rating system that will be used to quantify the subjective feeling of ease to expectorate. The VAS is represented by a horizontal line marked 0 to 10, where &quot;0&quot; indicates &quot;very easy to expectorate&quot; and &quot;10&quot; indicates &quot;not easy to expectorate at all&quot;. The lower the score, the easier it is to expectorate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Autogenic drainage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will have to perform a 30-min session of autogenic drainage. Sputum will be collected during the session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIMEOX + Autogenic drainage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will have to perform a 30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during the session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autogenic drainage</intervention_name>
    <description>Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.</description>
    <arm_group_label>Autogenic drainage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIMEOX + Autogenic drainage</intervention_name>
    <description>SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.</description>
    <arm_group_label>SIMEOX + Autogenic drainage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with cystic fibrosis

          -  Chronic bronchorrhea, able to expectorate by themselves

          -  Hospitalized

        Exclusion Criteria:

          -  Regular use of SIMEOX,

          -  Difficulties in understanding instructions,

          -  Severe cardiac comorbidity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Poncin, PT, PhD</last_name>
    <phone>+3227642316</phone>
    <email>william.poncin@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliana RFF de Macedo, PT, MSc</last_name>
    <email>juliana.ribeiro@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <state>Brussels Capital</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Poncin</last_name>
      <phone>+320470592032</phone>
      <phone_ext>+320470592032</phone_ext>
      <email>william.poncin@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Poncin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

